Prodotti GS / Area Kite
ZUMA-7 Study Results
![Immagine News](/media/f0kftzcu/3d-illustration-t-cells-car-t-ss-feature.jpg?center=0.61011904761904767,0.7466666666666667&mode=crop&width=722&height=442)
Kite announces Yescarta car t-cell therapy improved event-free Survival by 60% over chemotherapy plus stem cell transplant in secondline Relapsed or refractory large b-cell lymphoma.
Read the full Press Release
Grazie per il tuo feedback!